Danske Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Danske Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.2K	Sell	300 -2,700	-90%	-$148K	﹤0.01%	747
2026 Q1	$169K	Sell	3,000 -4,200	-58%	-$245K	﹤0.01%	664
2025 Q4	$428K	Sell	7,200 -108,424	-94%	-$5.9M	﹤0.01%	634
2025 Q3	$6.26M	Buy	115,624 +7,123	+7%	+$407K	0.02%	509
2025 Q2	$5.96M	Buy	108,501 +23,930	+28%	+$1.41M	0.01%	516
2025 Q1	$5.98M	Buy	84,571 +4,479	+6%	+$301K	0.02%	503
2024 Q4	$5.26M	Buy	80,092 +7,827	+11%	+$524K	0.02%	526
2024 Q3	$5.08M	Sell	72,265 -1,300	-2%	-$109K	0.02%	546
2024 Q2	$6.06M	Sell	73,565 -31,922	-30%	-$2.66M	0.02%	496
2024 Q1	$9.21M	Buy	+105,487	New	+$9.44M	0.03%	431

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Danske Bank's BMRN Position: Q2 2026 in Review

Danske Bank reduced its BioMarin Pharmaceuticals (BMRN) stake by 90% in Q2 2026, selling an estimated $148K and leaving 300 shares worth $17.2K. The position accounts for ﹤0.01% of the portfolio, ranked #747.

Danske Bank first reported a position in BMRN in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.21M in Q1 2024. 428 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Danske Bank held 300 shares of BioMarin Pharmaceuticals worth $17.2K as of Q2 2026.
Danske Bank sold 2,700 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $148K.
BioMarin Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #747 holding.
Danske Bank first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Danske Bank's BioMarin Pharmaceuticals position peaked at $9.21M in Q1 2024.
428 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.